Sutro Biopharma, Inc.
310 Utah Avenue, Suite 150
South San Francisco, CA 94080
September 24, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
| Attention: | John Reynolds, Assistant Director |
Irene Barberena-Meissner, Staff Attorney |
Kevin Dougherty, Staff Attorney |
Ethan Horowitz, Accounting Branch Chief |
Wei Lu, Staff Accountant |
| Re: | Sutro Biopharma, Inc. Registration Statement on Form S-1 (File No. 333-227103) |
originally filed August 29, 2018, as amended, and corresponding Registration Statement |
on Form 8-A (File No. 001-38662) filed September 18, 2018 |
Requested Date: September 26, 2018
Requested Time: 4:00 PM Eastern Time
Ladies and Gentlemen:
Sutro Biopharma, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to declare the above-captioned Registration Statements on Form S-1 and Form 8-A effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Amanda L. Rose, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Freedman at (650) 335-7292 or, in his absence, Ms. Rose at (206) 389-4553.
* * *
| Sincerely, | ||
| SUTRO BIOPHARMA, INC. | ||
| By: | /s/ Edward Albini | |
| Edward Albini | ||
| Chief Financial Officer | ||
| cc: | William J. Newell, Chief Executive Officer |
Sutro Biopharma, Inc.
Robert A. Freedman, Esq.
Amanda L. Rose, Esq.
Fenwick & West LLP
